Estrogen changes and prolactinoma tumor size
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This study looks at how changes in estrogen before diagnosis affect the growth of prolactin-secreting pituitary tumors (prolactinomas). The goal is to understand why some tumors are larger than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman, 18 years or older.
- You have been diagnosed with a prolactin-secreting pituitary tumor (smaller than 10 mm or 10 mm or larger) between 2013 and 2023.
- You have had at least some follow-up care at Hôpital Louis Pradel in Lyon, France.
- Your diagnosis was confirmed by MRI and elevated prolactin levels in the blood.
- You do not have a known genetic condition that causes these tumors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of the drug cabergoline to see if it works better for small prolactin-secreting tumors (microprolactinomas) in premenopausal women who have not been treated before. It aims to find a safe and effective way to lower high prolactin levels and shrink the tumor.
This research study investigates tumors and disorders of the pituitary gland (a small gland that controls many body hormones) and related areas of the brain. You may qualify if you have a pituitary tumor or disorder, or if you have a family history of these conditions.
This study looks at metabolic health (like blood sugar and cholesterol) in people with prolactinomas who are being treated with the drug cabergoline. It aims to understand how lowering prolactin affects the body's metabolism and may help guide better care for patients with this condition.
This study follows people who have Multiple Endocrine Neoplasia type 1 (MEN1), a genetic condition that can cause tumors in hormone glands. It aims to monitor symptoms and lesions over time to better understand how the condition progresses and how to manage it.
This trial compares medicine (bromocriptine) and surgery for people with a certain type of pituitary tumor (prolactinoma) that has not spread too far. It aims to see which approach works best and is safest for you.
This trial tests a drug called pasireotide for people with prolactinoma (a type of pituitary tumor) who cannot use standard dopamine agonist medicines or whose tumors do not shrink enough with them. It may be an option if surgery isn't right for you.
Hear when a new Prolactinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.